A case of relapsing HR+ metastatic breast cancer

Transcription: Jules Cohen, MD: Let’s go to clinical scenario #2. In December 2010, a 64-year-old woman with ER [estrogen receptor]–positive, PR [progesterone receptor]–negative, HER2 [human epidermal growth factor receptor 2]–negative invasive ductal carcinoma of the left breast received adjuvant anastrozole [Arimidex], presumably after all surgical and other appropriate therapies. Seventeen months later, she presents with […]

Scroll to top